A Dose-finding Study of JMKX003142 in Treatment of Cardiac Edema

Inclusion Criteria

• •1. Can fully understand the purpose and process of the study and voluntarily sign the informed consent form;
• •2. Age ≥ 18 years old when signing the informed consent form;
• •3. At the screening stage, it has been definitely diagnosed as heart failure, and it is combined with one of the following clinical manifestations related to body fluid retention: edema of both lower limbs, jugular vein engorgement, pulmonary congestion;
• •4. The screening phase is currently undergoing or preparing to use one of the following diuretic therapy as background treatment during the run-in period:
• •1\) At least 40mg/day of furosemide equivalent loop diuretics; 2) Any dose of loop diuretics combined with thiazide diuretics; 3) Any dose of loop diuretics combined with aldosterone receptor antagonists or other potassium sparing diuretics.
• •5\. After the background treatment in the run-in period, the subject still has the following two conditions:
• •1. One of the following clinical manifestations related to fluid retention still exists after the induction phase treatment: edema of both lower limbs, jugular vein dilatation, pulmonary congestion;
• •2. During the import phase, the weight of D-1 does not change by more than 1.0 kg compared to D-3.